Praxis Precision Medicines (PRAX) Competitors $46.32 +3.15 (+7.30%) Closing price 04:00 PM EasternExtended Trading$46.42 +0.10 (+0.22%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRAX vs. PTGX, AAPG, SRRK, MTSR, KYMR, VKTX, MOR, CRNX, ALVO, and MLTXShould you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), Metsera (MTSR), Kymera Therapeutics (KYMR), Viking Therapeutics (VKTX), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Praxis Precision Medicines vs. Its Competitors Protagonist Therapeutics Ascentage Pharma Group International Scholar Rock Metsera Kymera Therapeutics Viking Therapeutics MorphoSys Crinetics Pharmaceuticals Alvotech MoonLake Immunotherapeutics Praxis Precision Medicines (NASDAQ:PRAX) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability. Do analysts recommend PRAX or PTGX? Praxis Precision Medicines presently has a consensus target price of $92.11, indicating a potential upside of 98.86%. Protagonist Therapeutics has a consensus target price of $66.10, indicating a potential upside of 30.40%. Given Praxis Precision Medicines' higher probable upside, equities analysts clearly believe Praxis Precision Medicines is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, PRAX or PTGX? Protagonist Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPraxis Precision Medicines$8.55M110.36-$182.82M-$10.72-4.32Protagonist Therapeutics$434.43M7.23$275.19M$0.7567.59 Do insiders and institutionals believe in PRAX or PTGX? 67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer PRAX or PTGX? In the previous week, Protagonist Therapeutics had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 5 mentions for Protagonist Therapeutics and 3 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 1.61 beat Protagonist Therapeutics' score of 0.43 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Protagonist Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is PRAX or PTGX more profitable? Protagonist Therapeutics has a net margin of 27.04% compared to Praxis Precision Medicines' net margin of -2,137.48%. Protagonist Therapeutics' return on equity of 9.22% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines-2,137.48% -50.42% -46.74% Protagonist Therapeutics 27.04%9.22%8.31% Which has more risk & volatility, PRAX or PTGX? Praxis Precision Medicines has a beta of 2.6, meaning that its share price is 160% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. SummaryProtagonist Therapeutics beats Praxis Precision Medicines on 12 of the 16 factors compared between the two stocks. Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAX vs. The Competition Export to ExcelMetricPraxis Precision MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$879.33M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-4.3221.3126.1719.90Price / Sales110.36278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book1.947.518.055.38Net Income-$182.82M-$55.05M$3.15B$248.50M7 Day Performance6.90%2.45%1.85%2.97%1 Month Performance16.32%7.33%4.81%6.02%1 Year Performance17.95%5.38%34.86%20.39% Praxis Precision Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRAXPraxis Precision Medicines3.2572 of 5 stars$46.32+7.3%$92.11+98.9%+4.8%$879.33M$8.55M-4.32110News CoveragePositive NewsPTGXProtagonist Therapeutics1.8705 of 5 stars$53.36+0.0%$66.10+23.9%+42.6%$3.31B$434.43M71.15120News CoverageAAPGAscentage Pharma Group InternationalN/A$37.15-0.6%N/AN/A$3.26B$134.35M0.00600Positive NewsSRRKScholar Rock3.6242 of 5 stars$33.28-2.2%$42.67+28.2%+315.3%$3.23B$33.19M-13.15140MTSRMetseraN/A$29.00-2.0%$55.00+89.7%N/A$3.11BN/A0.0081Gap DownKYMRKymera Therapeutics3.1183 of 5 stars$46.29+0.9%$59.82+29.2%+43.6%$2.99B$47.07M-14.93170Positive NewsInsider TradeAnalyst RevisionVKTXViking Therapeutics4.1658 of 5 stars$24.86-4.4%$87.15+250.6%-51.8%$2.92BN/A-21.6220MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730CRNXCrinetics Pharmaceuticals3.5845 of 5 stars$29.91-0.8%$74.56+149.3%-38.3%$2.82B$1.04M-7.83210ALVOAlvotech3.354 of 5 stars$9.13-2.4%$18.00+97.2%-26.6%$2.82B$491.98M24.681,032MLTXMoonLake Immunotherapeutics2.2666 of 5 stars$44.87+3.1%$78.71+75.4%+11.5%$2.78BN/A-19.512Positive News Related Companies and Tools Related Companies Protagonist Therapeutics Competitors Ascentage Pharma Group International Competitors Scholar Rock Competitors Metsera Competitors Kymera Therapeutics Competitors Viking Therapeutics Competitors MorphoSys Competitors Crinetics Pharmaceuticals Competitors Alvotech Competitors MoonLake Immunotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRAX Stock Alerts